Nouveau Life Pharmaceuticals, Inc.
NOUV · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2008 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | -0.75 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.07% |
| EV / EBITDA | 0.00 | 0.00 | -0.78 | -95.22 |
| Quality | ||||
| ROIC | 0.00% | 0.00% | -267.75% | 38.05% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -0.03 | 0.00 | 0.04 | 0.13 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 2,489.51% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | 0.49 | -1.18 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 6.36 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |